NIKA NIKA PHARMACEUTICALS, INC
Pharmaceutical Preparations · OTC · SEC CIK 1145604 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-60.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-574.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets6,574.0%
Debt / equity—
Current ratio0.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-85.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $0 | $0 | $0 | $0 |
| SG&A expense | $53,026 | $35,174 | $64,833 | $33,715 | $14,712 |
| Operating income | -$76,398 | -$95,792 | -$64,833 | -$3.18M | -$14,712 |
| Pretax income | -$76,398 | -$95,792 | -$64,833 | -$3.18M | -$14,712 |
| Net income | -$76,398 | -$95,792 | -$64,833 | -$3.18M | -$14,712 |
| EPS (basic) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 1.05B | 1.02B | 876.09M | 723.95M | 396.09M |
| Balance sheet | |||||
| Cash & equivalents | $1,889 | $2,083 | $19,596 | $864 | $399 |
| Current assets | $20,996 | $17,934 | $19,596 | $864 | $399 |
| Total assets | $20,996 | $17,934 | $19,596 | $864 | $399 |
| Current liabilities | $318,624 | $239,164 | $101,745 | $18,180 | $10,518 |
| Short-term debt | $318,624 | $239,164 | $101,745 | $18,180 | — |
| Total liabilities | $318,624 | $239,164 | $101,745 | $18,180 | $24,018 |
| Shareholders' equity | -$297,628 | -$221,231 | -$82,149 | -$17,316 | -$23,619 |
| Shares outstanding | 1.05B | 1.05B | 876.09M | 876.09M | 396.09M |
| Cash flow statement | |||||
| Operating cash flow | -$79,654 | -$154,932 | -$64,833 | $33,715 | $14,712 |
| Financing cash flow | $79,460 | $137,419 | $83,565 | $34,180 | $13,500 |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.